Table 1.

Baseline demographic, clinico-pathologic data, and DSA characteristics of study patients by C3d status.

	All (N=106)	C3d− (N=25)	C3d+ (N=81)	P-value
Patient Characteristics
Gender (% male)	54.7%	52%	55.6%	0.82
Age at transplant (mean ± std)	39.6 ± 15.5	43.6 ± 13.9	38.3 ± 15.8	0.14
Age at enrollment (mean ± std)	44.4 ± 14.9	46.9 ± 14.2	43.7 ± 15.1	0.35
Race:
White (%)	65.1%	80%	60.5%	0.19
Black (%)	23.6%	12%	27.2%
Other (%)	11.3%	8%	12.3%
Time to biopsy (yrs)	5.3 ± 5.0	3.92 ± 3.42	5.66 ± 5.38	0.13
No. HLA A/B/DRB1 mismatches	3.86 ± 1.46	3.59 ± 1.53	3.95 ± 1.43	0.32
Creatinine at biopsy (mg/dL)	2.71 ± 1.60	2.08 ± 0.89	2.88 ± 1.71	0.03
Creatinine at biopsy (μmol/L)	239.2 ± 141.6	183.8 ± 78.7	254.9 ± 151.6	0.03
Protein/Cr ratio (mg/g)	1515.0 ± 1696.0	923.0 ± 1110.1	1735.3 ± 1830.0	0.10
Protein/Cr ratio (mg/mmol)	171.2 ± 191.6	104.3 ± 125.4	196.1 ± 206.8	0.10
DSA Characteristics (%)
Class I only	5.7%	4%	6.2%
Class II only	69.8%	80%	66.7%
Class I and II	24.5%	16%	27.1%
DSA to HLA-A	9.6%	5.3%	10.5%
DSA to HLA-B	10.0%	7.9%	10.5%
DSA to HLA-C	0.9%	0%	1.1%
DSA to HLA-DR	38.4%	34.2%	39.2%
DSA to HLA-DQ	41.1%	52.6%	38.7%
Number of DSA (mean ± std)	2.1 ± 1.4	1.5 ± 0.7	2.2 ± 1.5	0.02
Biopsy Banff Scores (mean ± std)
g	0.63 ± 0.74	0.72 ± 0.84	0.59 ± 0.71	0.46
ptc	1.27 ± 0.93	1.26 ± 0.93	1.27 ± 0.94	0.98
t	0.95 ± 1.17	0.96 ± 1.17	0.95 ± 1.18	0.97
i	1.02 ± 1.11	0.96 ± 1.14	1.04 ± 1.11	0.76
v	0.10 ± 0.36	0.04 ± 0.20	0.11 ± 0.39	0.37
cg	0.69 ± 1.06	0.44 ± 0.82	0.77 ± 1.12	0.17
ci	1.39 ± 1.00	1.08 ± 0.70	1.49 ± 1.06	0.07
ct	1.56 ± 0.86	1.20 ± 0.65	1.67 ± 0.89	0.02
Microvascular inflammation (%)a	78.9%	76.0%	79.7%	0.78
Moderate-severe IFTA (%)b	37.7%	20.0%	44.3%	0.035
C4d+ (%)	62.4%	29.2%	72.7%	0.0002

^ag+ptc >0;

^bci+ct ≥2.